The current CLBS market cap is 3.48M. The company's latest EPS is USD -2.5571 and P/E is -1.11.
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Operating Income | -37.72M | -6.54M | -6.84M | -6.88M | -5.96M |
Net Income | -37.38M | -5.99M | -6.19M | -4.03M | -5.26M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Operating Income | -20.09M | -19.15M | -29.05M | -57.6M | -25.71M |
Net Income | -19.36M | -8.15M | -27.47M | -54.23M | -20.84M |
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
Total Assets | 78.53M | 73.03M | 66.33M | 62.37M | 58.09M |
Total Liabilities | 6.76M | 6.71M | 5.62M | 4.65M | 5.39M |
Total Equity | 71.77M | 66.32M | 60.7M | 57.71M | 52.7M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
Total Assets | 27.15M | 36M | 97.01M | 73.03M | 54.69M |
Total Liabilities | 6.6M | 3.76M | 5.01M | 6.71M | 6.8M |
Total Equity | 20.55M | 32.24M | 92M | 66.32M | 47.89M |
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
Operating | -14.7M | -21.17M | -8.2M | -12.38M | -15.96M |
Investing | 21.81M | 28.91M | 4.29M | 3.56M | 15.82M |
Financing | -238k | -224k | -85k | 367k | 361k |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
Operating | -18.88M | -8.82M | -22.25M | -21.17M | -20.03M |
Investing | 21.43M | -7.28M | -54.9M | 28.91M | 10.1M |
Financing | 1.18M | 18.58M | 85.28M | -224k | 385k |
Market Cap | 3.48M |
Price to Earnings Ratio | -1.11 |
Price to Sales Ratio | 0 |
Price to Cash Ratio | 1.02 |
Price to Book Ratio | 0.48 |
Dividend Yield | - |
Shares Outstanding | 8.15M |
Average Volume (1 week) | 0 |
Average Volume (1 Month) | 0 |
52 Week Change | - |
52 Week High | - |
52 Week Low | - |
Spread (Intraday) | 0 (0.84%) |
Company Name | Caladrius Biosciences Inc |
Address |
651 n broad st suite 201 wilmington, delaware 19709 |
Website | https://www.caladrius.com |
Industry | insurance carriers, nec (6399) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.